Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 7, 2022 4:05 PM ESTPlans to submit 24-month Phase 3 data to the FDA for intravitreal pegcetacoplan for geographic atrophy (GA); expected PDUFA target action date in February 2023EU marketing authorization application submission on track for December 2022Reported 24-month data with pegcetacoplan in GA showing increased effects over time and continued favorable safety profileAchieved $17.7 million in Q3 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenuesCash and investments of $708.6 million as of Sept. 30, 2022; expected cash runway into Q1 2024Conference call scheduled today at 4:30 p.m. ET
WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) --... More
